{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:40:10Z","timestamp":1780375210875,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi Greece"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12902-019-0364-5","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T10:03:36Z","timestamp":1556186616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies"],"prefix":"10.1186","volume":"19","author":[{"name":"AGREEMENT Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Liatis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Iraklianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos","family":"Kazakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Mastorakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Milios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zadalla","family":"Mouslech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noutsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Pagkalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sampanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782\u20137.","journal-title":"Nature"},{"key":"364_CR2","unstructured":"Diabetes\u00a0Control and\u00a0Complications\u00a0Trial Research Group,\u00a0Nathan DM,\u00a0Genuth S,\u00a0Lachin J,\u00a0Cleary P,\u00a0Crofford O,\u00a0Davis M,\u00a0Rand L,\u00a0Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977\u2013986."},{"key":"364_CR3","doi-asserted-by":"crossref","unstructured":"UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).\u00a0 Lancet. 1998;352:837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"1","key":"364_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"key":"364_CR5","unstructured":"Hellenic Diabetes Association (EDE). 2016 [cited 2016 Jan 15]. Available from: \n                    http:\/\/www.ede.gr\/wp-content\/uploads\/2012\/odigies.pdf"},{"key":"364_CR6","unstructured":"IDF Diabetes Atlas 7th edition. 2016 [cited 2016 Nov 27]. Available from \n                    www.idf.org\/diabetesatlas"},{"key":"364_CR7","doi-asserted-by":"crossref","unstructured":"Garber AJ,\u00a0Abrahamson MJ,\u00a0Barzilay JI,\u00a0Blonde L,\u00a0Bloomgarden ZT,\u00a0Bush MA,\u00a0Dagogo-Jack S,\u00a0DeFronzo RA,\u00a0Einhorn D,\u00a0Fonseca VA,\u00a0Garber JR,\u00a0Garvey WT,\u00a0Grunberger G,\u00a0Handelsman Y,\u00a0Henry RR,\u00a0Hirsch IB,\u00a0Jellinger PS,\u00a0McGill JB,\u00a0Mechanick JI,\u00a0Rosenblit PD,\u00a0Umpierrez GE. American\u00a0Association\u00a0of\u00a0Clinical Endocrinologists\u00a0(AACE);\u00a0American\u00a0College\u00a0of\u00a0Endocrinology\u00a0(ACE) Consensus\u00a0statement\u00a0by the\u00a0American Association\u00a0of Clinical Endocrinologists\u00a0and\u00a0American College\u00a0of Endocrinology\u00a0on the\u00a0comprehensive\u00a0type\u00a02\u00a0diabetes\u00a0management\u00a0algorithm--2016\u00a0executive\u00a0summary. Endocr Pract.\u00a02016;22:84\u2013113.","DOI":"10.4158\/EP151126.CS"},{"key":"364_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.clinthera.2006.03.005","volume":"28","author":"KM Fox","year":"2002","unstructured":"Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2002;28:388\u201395.","journal-title":"Clin Ther"},{"key":"364_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clinthera.2007.02.012","volume":"29","author":"N Yurgin","year":"2007","unstructured":"Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther. 2007;29:316\u201325.","journal-title":"Clin Ther"},{"key":"364_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.diabet.2007.02.003","volume":"33","author":"B Eliasson","year":"2007","unstructured":"Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbj\u00f6rnsd\u00f3ttir S, Steering Committee of the Swedish National Diabetes Register (NDR). Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab. 2007;33:269\u201376.","journal-title":"Diabetes Metab"},{"key":"364_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Casagrande","year":"2013","unstructured":"Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals among people with diabetes, 1988\u20132010. Diabetes Care. 2013;36:2271\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"364_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.diabres.2014.08.002","volume":"106","author":"T Wilke","year":"2014","unstructured":"Wilke T, Groth A, Fuchs A, Seitz L, Kienh\u00f6fer J, Lundershausen R, Maywald U. Real life treatment of diabetes mellitus type 2 patients: an analysis based on a large sample of 394,828 German patients. Diabetes Res Clin Pract. 2014;106(2):275\u201384.","journal-title":"Diabetes Res Clin Pract"},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/dc12-1759","volume":"36","author":"M Stone","year":"2013","unstructured":"Stone M, Charpentier G, Doggen K, Kuss O, Lindblad U, Kellner C, Nolan J, Pazderska A, Rutten G, Trento M, Khunti K, GUIDANCE Study Group. Quality of Care of People with Type 2 diabetes in eight European countries. Diabetes Care. 2013;36:2628\u201338.","journal-title":"Diabetes Care"},{"key":"364_CR14","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","volume":"32","author":"JR Banegas","year":"2011","unstructured":"Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Mass\u00f3-Gonz\u00e1lez EL, Jim\u00e9nez FJ, Perk J, Steg PG, De Backer G, Rodr\u00edguez-Artalejo F. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143\u201352.","journal-title":"Eur Heart J"},{"key":"364_CR15","first-page":"1","volume":"23","author":"S Liatis","year":"2014","unstructured":"Liatis S, Papaoikonomou S, Ganotopoulou A, Papazafiropoulou A, Dinos C, Michail M, Xilomenos A, Melidonis A, Pappas S. Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study. BMC Endocr Disord. 2014;23:1\u20138.","journal-title":"BMC Endocr Disord"},{"key":"364_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cen.12119","volume":"80","author":"P Pablos-Velasco De","year":"2014","unstructured":"De Pablos-Velasco P, Parhofer KG, Bradley C, Eschw\u00e8ge E, G\u00f6nder-Frederick L, Maheux P, Wood I, Simon D. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol. 2014;80:47\u201356.","journal-title":"Clin Endocrinol"},{"key":"364_CR17","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1001\/jama.2014.5951","volume":"311","author":"A Wallia","year":"2014","unstructured":"Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311:2315\u201325.","journal-title":"JAMA"},{"issue":"5","key":"364_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1463-1326.2009.01138.x","volume":"11","author":"AJ Garber","year":"2009","unstructured":"Garber AJ. The importance of titrating starting insulin regimens in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(5):10\u20133.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"364_CR19","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin R, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673\u20139.","journal-title":"Diabetes Care"},{"key":"364_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/VHRM.S33934","volume":"9","author":"B Ahr\u00e9n","year":"2013","unstructured":"Ahr\u00e9n B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Man. 2013;9:155\u201363.","journal-title":"Vasc Health Risk Man"},{"issue":"1","key":"364_CR21","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S1751-9918(10)60004-6","volume":"4","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR, Knunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4(1):S11\u20138.","journal-title":"Prim Care Diabetes"},{"key":"364_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"issue":"2","key":"364_CR23","doi-asserted-by":"publisher","first-page":"00037","DOI":"10.15406\/jdmdc.2015.02.00037","volume":"2","author":"G Koukoulis","year":"2015","unstructured":"Koukoulis G, Melidonis A, Milios K, Mellita Investigators. Quality of life of insulin-Na\u00efve people with type 2 diabetes mellitus inadequately controlled on Oral antidiabetic drugs after the addition of insulin glargine, in every day clinical practice in Greece. J Diabetes Metab Disord Control. 2015;2(2):00037.","journal-title":"J Diabetes Metab Disord Control"},{"key":"364_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/dom.12484","volume":"17","author":"RW Thomsen","year":"2015","unstructured":"Thomsen RW, Baggesen LM, Svensson E, Pedersen L, N\u00f8rrelund H, Buhl ES, Haase CL, Johnsen SP. Early glycaemic control among patients with type 2 diabetes and initial glucose lowering treatment: a 13-year population based cohort study. Diabetes Obes Metab. 2015;17:771\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"364_CR25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s00125-015-3698-1","volume":"58","author":"RW Thomsen","year":"2015","unstructured":"Thomsen RW, Baggesen LM, Sogaard M, Pedersen L, N\u00f8rrelund H, Buhl ES, Haase CL, Johnsen S. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia. 2015;58:2247\u201353.","journal-title":"Diabetologia"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0364-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0364-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0364-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:16:14Z","timestamp":1587683774000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0364-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0364-5","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"15 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by all Hospitals\u2019 Review Boards and conducted in accordance with Good Pharmacoepidemiology Practices (GCPs) and all applicable regulations. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Stavros Liatis has received research support and\/or consulting honoraria from Astra-Zeneca, Boeringer Ingelheim, MSD, Novartis, Novo Nordisk, Sanofi, Pharmaserve Lilly and ELPEN and is a member of the Editorial Board of BMC Endocrine Disorders.Dr. Styliani Iraklianou has received research support and consulting honoraria from Sanofi.Dr. Kyriakos Kazakos has received research support and\/or consulting honoraria from Astra Zeneca, Sanofi Aventis, Novo Nordisk and Lilly.Pr. George Mastorakos declares no conflict of interest.Kostas Milios is an employee of Sanofi working as Field Medical for Greece.Dr. Zadalla Mouslech has received research support and\/or consulting honoraria from Sanofi and Lilly.Dr. Marina Noutsou has received research support and\/or consulting honoraria from Novo Nordisk, Sanofi Aventis, Lilly, Boehringer Ingelheim, ELPEN and Astra Zeneca.Dr. Emmanouil Pagkalos has received research support and\/or consulting honoraria from Astra Zeneca, Bayer, \u0392\u0399\u0391\u039d\u0395\u03a7, Boehringer Ingelheim, ELPEN, Galenica, GSK, Jansen, Lilly, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and Winmedica.Dr. Christos Sampanis has received research support and \/or consulting honoraria from Novo Nordisk, Sanofi and Lilly Co.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}